P4–291: Predicting <i>in vivo</i> BACE inhibitor efficacy: Are human iPS‐derived neurons superior?
Christine Oborski(ProterixBio (United States)), David Riddell(Eli Lilly (United States)), Stephen Noell(Pfizer (United States)), Leslie R. Pustilnik(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Sandra J. Engle(Biogen (United States)), Cheng Chang(Pfizer (United States)), Kewa Mou(Pfizer (United States)), Yao Zhang(Xiamen University), Michael A. Brodney(Vertex Pharmaceuticals (United States)), Yasong Lu(Pfizer (United States)), Charles E. Nolan(Pfizer (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302